天津科学技术出版社
经鼻吸入间充质干细胞来源的细胞外囊泡治疗急性肺损伤的作用与机制研究
刘浩正 ,孙宜宣 ,刘鑫楷 ,刘思成 ,李瑞 ,傅恩泽 ,李宗金 *
作者信息
  1.  南开大学医学院,天津 300350
*通信作者

摘要

目的 探索一种具有高疗效与良好临床转化潜力的急性肺损伤(ALI)治疗新策略:经鼻吸入途径递送间充质干细胞来源的细胞外囊泡(MSC-EVs),系统评估其对脂多糖(LPS)诱导的 ALI 的治疗效果,并初步揭示其治疗机制。 方法 从人脐带间充质干细胞(hUC-MSCs)的培养基上清中提取并鉴定 MSC-EVs。 通过气管滴注 LPS建立小鼠 ALI 模型后,采用经鼻吸入方式进行干预。 24 h 后,综合运用肺组织苏木素-伊红(HE)染色、免疫荧光染色、肺泡灌洗液(BALF)细胞学与生化分析以及实时荧光定量聚合酶链式反应(RT-qPCR)检测炎症因子白细胞介素-6(IL-6)等多项指标,全面评估疗效。 进一步通过生物信息学方法,预测 MSC-EVs 中关键微小 RNAs (miRNAs)的靶基因,并进行京都基因与基因组数据库(KEGG)通路富集分析,从分子网络层面探究其潜在作用机制。 结果 经鼻吸入 MSC-EVs 能显著改善 ALI 小鼠的肺组织病理损伤。 与损伤组相比,损伤后MSC-EVs治疗组的肺组织病理情况及免疫细胞浸润程度均得到明显改善。 生物信息学分析揭示,MSC-EVs 中富含的miRNAs可能通过调控丝裂原活化蛋白激酶(MAPK)、磷脂酰肌醇 3 -激酶(PI3K) -蛋白激酶 B (PKB/ Akt)等关键信号通路,参与炎症抑制、细胞凋亡调控及组织修复过程。 结论 经鼻吸入能有效将MSC-EVs递送至肺部,其作用机制与直接缓解肺部病理损伤、调节局部免疫反应及影响多条修复相关信号通路密切相关。 该研究为开发基于MSC-EVs的吸入式生物制剂、推动 ALI 的临床治疗提供了重要的实验依据与新颖思路。

Study on the efficacy and mechanism of intranasal inhalation of mesenchymal stem cell-derived extracellular vesicles in treating acute lung injury
Haozheng LIU , Yixuan SUN , Xinkai LIU , Sicheng LIU , Rui LI , Enze FU , Zongjin LI *
Author Information
  1.  Nankai University School of Medicine, Tianjin 300350, China
*Corresponding author

Abstract

Objective To explore a novel therapeutic strategy for acute lung injury (ALI) with high efficacy and favorable clinical translational potential by delivering mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) via the intranasal route and to systematically evaluate the therapeutic effects of MSC-EVs in a lipopolysaccharide ( LPS) induced ALI model and further provided initial insights into the underlying mechanisms. Methods MSC-EVs were isolated and characterized from the conditioned medium of human umbilical cord MSCs (hUC-MSCs). Following the establishment of a mouse ALI model via intratracheal instillation of LPS, the intervention was administered through intranasal inhalation. Twenty-four hours post-intervention, a comprehensive assessment of therapeutic efficacy was conducted. This included histological evaluation of lung tissues via hematoxylin-eosin (HE) staining, immunofluorescence staining, cytological and biochemical analysis of bronchoalveolar lavage fluid (BALF), and quantification of the inflammatory cytokine interleukin-6 (IL-6) using real-time reverse transcription quantitative polymerase chain reaction (RT-PCR). Furthermore, bioinformatics approaches were employed to predict the target genes of key microRNAs ( miRNAs) contained within the MSC-EVs. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was subsequently performed to explore the potential molecular network mechanisms underlying their therapeutic effects. Results Intranasal inhalation of MSC-EVs significantly ameliorated pulmonary histopathological damage in ALI mice. Compared to the injury group, the MSC-EVs treatment group showed marked improvements in lung histopathology and the extent of immune cell infiltration following injury. Bioinformatics analysis revealed that the miRNAs enriched in MSC-EVs may participate in processes such as inflammation suppression, apoptosis regulation, and tissue repair, potentially by modulating key signaling pathways including mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)-protein kenase B (PKB/ Akt). Conclusion This study systematically demonstrates that intranasal inhalation effectively delivers MSC-EVs to the lungs. The therapeutic effects are closely associated with direct attenuation of pulmonary pathological damage, modulation of local immune responses, and regulation of multiple repair-related signaling pathways. Collectively, these findings provide important experimental evidence and novel insights for the development of MSC-EV-based inhalable biologics and for advancing the clinical treatment of ALI.

利益冲突:作者均声明无利益冲突

再生医学研究 Copyright © 2026. All Rights Reserved